LON:HCM HUTCHMED (HCM) Share Price, News & Analysis GBX 192 -8.00 (-4.00%) As of 09/11/2026 12:29 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsNews and Trends About HUTCHMED Stock (LON:HCM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HUTCHMED alerts:Sign Up Key Stats Today's Range 190▼ 19550-Day Range 165▼ 21252-Week Range 150.48▼ 266Volume6,883 shsAverage Volume37,897 shsMarket Capitalization£1.67 billionP/E Ratio96.00Dividend Yield4.63%Price TargetN/AConsensus RatingN/A Company Overview We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S. We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13). Read More Receive HCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HCM Stock News HeadlinesHUTCHMED (LON:HCM) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?September 11 at 2:22 AM | americanbankingnews.comCiti Sticks to Its Buy Rating for HUTCHMED (China) (HCM)September 6, 2026 | theglobeandmail.comThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Chaikin Money Flow indicator has a new top retirement pick. The company holds three fast-growing businesses -- including an autonomous vehicle unit and a streaming service with 10x Netflix's reach -- any of which could be spun off in the next 12 to 24 months. It also pays a dividend, a rarity among high-growth AI names. Chaikin lays out the full case in a new free presentation, no email or credit card required.September 12 at 1:00 AM | Chaikin Analytics (Ad)Positive Report for HUTCHMED (China) (HCM) from DaiwaSeptember 5, 2026 | theglobeandmail.comBiggest stock movers Thursday: AVGO, SNOW, HPE, and moreSeptember 3, 2026 | seekingalpha.comHUTCHMED (LON:HCM) Stock Passes Below Two Hundred Day Moving Average - Here's WhySeptember 2, 2026 | americanbankingnews.comHUTCHMED (China) Limited: HUTCHMED Announces NMPA Approval for ATLED (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic CholangiocarcinomaAugust 28, 2026 | finanznachrichten.deHUTCHMED Announces China NMPA Conditional Approval of ATLED for FGFR2 Fusion-Positive Intrahepatic CholangiocarcinomaAugust 27, 2026 | quiverquant.comQSee More Headlines HCM Stock Analysis - Frequently Asked Questions How have HCM shares performed this year? HUTCHMED's stock was trading at GBX 209 at the beginning of the year. Since then, HCM shares have decreased by 8.1% and is now trading at GBX 192. How do I buy shares of HUTCHMED? Shares of HCM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of HUTCHMED own? Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include Associated British Foods (ABF), Chaarat Gold (CGH), Bank of America (BAC), Fossil Group (FOSL), AMC Entertainment (AMC) and Air Canada (AC). Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolLON:HCM CIKN/A Webwww.chi-med.com Phone+85221213888FaxN/AEmployees1,760Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 2 Trailing P/E Ratio96.00 Forward P/E Ratio39.60 P/E GrowthN/ANet Income-£52.98 million Net Margins163.84% Pretax MarginN/A Return on Equity36.88% Return on Assets-5.90% Debt Debt-to-Equity Ratio7.91 Current Ratio4.96 Quick Ratio2.97 Sales & Book Value Annual Sales£549.12 million Price / Sales3.04 Cash FlowGBX 76.96 per share Price / Cash Flow2.49 Book ValueGBX 87.44 per share Price / Book2.20Miscellaneous Outstanding Shares869,071,000Free FloatN/AMarket Cap£1.67 billion OptionableNot Optionable Beta0.43 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (LON:HCM) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe retirement income that answers “yes” when everything else says noTodd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...Eagle Publishing | SponsoredMy ‘one day’ retirement secretTradeSmith's AI research team, backed by a $17 million investment and led by a former NSA codebreaker, built a...TradeSmith | Sponsored17 Nobel Prize winners… one startling warningOn July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...Porter & Company | Sponsoredyour job is on the listThe CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HCM Stock Alerts